Patients with Advanced Disease: The Value of Patient Reported Outcomes

Jan Gaertner\textsuperscript{a,b} Gerhild Becker\textsuperscript{a,b}

\textsuperscript{a}Department of Palliative Care, University Medical Center Freiburg, \textsuperscript{b}Competence Center Palliative Care Baden-Württemberg (KOMPACT), Freiburg i.Br., Germany

In this issue of \textit{Oncology Research and Treatment}, Jürg Bernhard and colleagues [1] present quality of life (Qol) data, findings from other patient reported outcome measures (PRO) and performance status assessments from a randomized controlled trial (RCT) of patients with advanced pancreatic cancer (median survival of their patients was 7–8 months). Survival data and other findings of the RCT have been reported earlier [1, 3]. Jürg Bernhard and his co-authors emphasize the value of measuring PRO and Qol of the patients to assess the actual benefit that patients may expect from disease modifying interventions in this incurable and life-limiting phase of the disease. They argue that in contrast to ‘tumor centered outcomes’ [1] such PRO and Qol measures are essential for a patient centered assessment of treatments’ effect on patients’ survival and wellbeing. In their study they specifically assessed whether ‘clinical benefit response’ (CBR), a combined measure of performance status, pain intensity, and body weight is associated with survival, and whether CBR reflects a wide-enough range of domains to adequately capture patients’ perception. The article adds substantially to the ongoing debate about the meaningful assessment of the effects of disease modifying interventions on the patients’ Qol and other PRO [4].

Meanwhile, the importance of thorough Qol and PRO assessments in clinical trials has been recognized by the public, leading research organizations, and drug approval authorities [5]. Notably, the present work of Bernhard et al. [1] was supported by both public and private funding. This may reflect the fact that also physician-researchers and pharmaceutical companies are increasingly interested in this topic [5].

Especially when caring for patients with advanced and life-limiting diseases, preserving Qol and reducing symptom burden are among the most important therapeutic goals [6]. This is not restricted to end-of-life care. Yet, it is equally important if the patients are in a good condition and still receive disease modifying interventions with a primarily life-prolonging intention [6]. A current survey among Europeans from different countries revealed that patients, relatives, and healthy interviewees highly value Qol if faced with terminal illness [7]. Unfortunately, it has also been reported that clinical trials from the field of advanced cancer care largely neglect the measurement of Qol and other PRO but almost exclusively rely on the measurement of survival and surrogate measures, such as progression free survival (PFS) [8, 9]. Even if Qol and other PRO are obtained in clinical trials, reporting and appraisal of these findings is frequently insufficient [8, 9]. Paradoxically, the publication process of the randomized controlled trial SAKK 44/00-CECOG/PAN.1.3.001 [3] that provided the data base for the study presented by Bernhard et al. [1] is a classic example. Although Qol and PRO data were obtained in the trial, authors of the primary publication did not report these findings [3]. The specific reasons for this are unclear, but obviously other findings were considered to be more important. Instead of Qol and PRO, the working group chose to publish other findings from the available secondary endpoints. This reflects common practice and should not be judged as a mistake of the working group around Bernhard and Herrmann. For example, even European Organization for Research and Treatment of Cancer (EORTC) working groups frequently decide on a step-by-step (sliced) publication strategy and separately publish the Qol and survival data of their elaborate RCT, as in extremely relevant multicenter EORTC trials about the effects of adjuvant whole brain radiotherapy [10, 11].

As stated above, in the primary publication of the trial SAKK 44/00-CECOG/PAN.1.3.001 by Herrmann et al. [3], findings for surrogate measures, such as PFS, were reported. PFS is a traditional and very frequently chosen primary or secondary outcome parameter in clinical trial protocols [12]. In the diction of Bernhard et al. [1], PFS is a classic choice of a ‘tumor-centered outcome’. The widespread use of PFS in advanced cancer trials is not unproblematic, especially if it is used as the primary endpoint [12]. A study for the U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality [12] reported that contradictory to physicians’ and researchers’ intuition, a correlation of PFS and overall survival is questionable for many cancers. The same was reported for the earlier assumption that PFS might correlate with Qol or psychological wellbeing.

\textsuperscript{a}Department of Palliative Care, University Medical Center Freiburg, \textsuperscript{b}Competence Center Palliative Care Baden-Württemberg (KOMPACT), Freiburg i.Br., Germany
Similar considerations as for QoL and other PRO are applicable for the patients’ performance status (which strictly speaking is another PRO). The performance status is a main component of the CBR assessed by Bernhard et al. [1]. The patients’ performance status is well known to be one of the most important prognostic indicators for the realistic benefits and harms patients may expect from disease modifying interventions in advanced disease [13]. It has been argued that patients with a lower Karnofsky or Eastern Cooperative Oncology Group (ECOG) score are at considerably higher risk of experiencing side effects from disease modifying therapies while they are less likely to benefit in terms of survival [13]. Although in clinical practice patients with ECOG 3 frequently receive such treatments, trials rarely provide data about the effect of these therapies on patients with such a rather reduced performance status [13]. This severely impedes a patient-centered shared decision-making process, since the information is essential to weigh the patients’ odds for experiencing benefits or harms from the available interventions [13].

The value of QoL and other PRO as reported by Bernhard et al. [1] is not only relevant for the research setting, but also for clinical practice. For example, Velikova et al. [14] reported that the mere addition of a comprehensive patient reported QoL measurement to the set of routine assessments (e.g. laboratory and radiologic testing) helps to increase the quality of cancer care. Meanwhile, the evidence base for such an approach is broad and the routine assessment of symptom burden, distress and/or QoL has been advocated by major treatment guidelines [6, 15]. Despite such evidence it should not be overlooked that currently few centers adhere to these recommendations [16, 17]. This is surprising, since for example the National Comprehensive Cancer Network (NCCN) has developed easy-to-use single item scales for this purpose [18].

Bernhard et al. should be congratulated for increasing our awareness for the value of QoL and other PRO measures in the care for patients with advanced and life-limiting disease. In the past years, ‘personalized therapy’ (in a genomic understanding) has become one of the main sources of truly meaningful progress in the care for these patients. Similarly, the routine adoption of PRO and QoL measures in trials and everyday practice may substantially add to the ‘personalization’ (in the sense of individualization) of care. Routinely weighing the impact of the available treatment option on the physical, psychological, social, and spiritual wellbeing of our patients will eventually lead to an even more patient-centered way of care.

Disclosure Statement

Jan Gaertner received research support from public funding (Federal Ministry of Education and Research, Germany) and private funding by pharmaceutical companies (Sanofi-Aventis, Mundipharma, TEVA/Cephalon), honoraria for lectures from pharmaceutical companies (Mundipharma, Grünenthal, Pfizer, Cephalon, TEVA, Archimedes), and has served on advisory boards for buccal Fentanyl (TEVA/Cephalon). Gerhild Becker received research support from public funding (Federal Ministry of Education and Research, Germany, German Cancer Aid) and private funding by pharmaceutical companies (Roche Pharma, Novartis Pharma, Mundipharma). She received honoraria for lectures from pharmaceutical companies (Mundipharma, Grünenthal, Pfizer, Cephalon) and she serves on an advisory board for Naxosegl (Astra Zeneca).

References


Gaertner/Becker